Back to Search Start Over

Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma

Authors :
Enfermería
Fisiología
Especialidades médico-quirúrgicas
Biología celular e histología
Erizaintza
Fisiologia
Medikuntza eta kirurgia espezialitateak
Zelulen biologia eta histologia
Larrinaga Embeita, Gorka
Solano Iturri, Jon Danel
Errarte Yarza, Peio
Unda Urzaiz, Jesús Miguel
Loizaga Iriarte, Ana
Pérez Fernández, Amparo
Echevarría Orella, Enrique
Asumendi Mallea, Aintzane
Manini, Claudia
Angulo, Javier C.
López Fernández de Villaverde, José Ignacio
Enfermería
Fisiología
Especialidades médico-quirúrgicas
Biología celular e histología
Erizaintza
Fisiologia
Medikuntza eta kirurgia espezialitateak
Zelulen biologia eta histologia
Larrinaga Embeita, Gorka
Solano Iturri, Jon Danel
Errarte Yarza, Peio
Unda Urzaiz, Jesús Miguel
Loizaga Iriarte, Ana
Pérez Fernández, Amparo
Echevarría Orella, Enrique
Asumendi Mallea, Aintzane
Manini, Claudia
Angulo, Javier C.
López Fernández de Villaverde, José Ignacio
Publication Year :
2021

Abstract

(1). Background: Immunohistochemical (IHC) evaluation of programmed death-1 (PD-1) and its ligand (PD-L1) is being used to evaluate advanced malignancies with potential response to immune checkpoint inhibitors. We evaluated both plasma and tissue expression of PD-1 and PD-L1 in the same cohort of patients, including non-metastatic and metastatic clear cell renal cell carcinoma (CCRCC). Concomitant plasma and tissue expression of PD-1 and PD-L1 was evaluated with emphasis on diagnostic and prognostic implications. (2) Methods: we analyzed PD-1 and PD-L1 IHC expression in tumor tissues and soluble forms (sPD-1 and sPD-L1) in plasma from 89 patients with CCRCC, of which 23 were metastatic and 16 received systemic therapy. The primary endpoint was evaluation of overall survival using Kaplan-Meier analysis and the Cox regression model. Plasma samples from healthy volunteers were also evaluated. (3) Results: Interestingly, sPD-1 and sPD-L1 levels were lower in cancer patients than in controls. sPD-1 and sPD-L1 levels and their counterpart tissue expression both at the tumor center and infiltrating front were not associated. Higher expression of both PD-1 and PD-L1 were associated with tumor grade, necrosis and tumor size. PD-1 was associated to tumor stage (pT) and PD-L1 to metastases. sPD-1 and sPD-L1 were not associated with clinico-pathological parameters, although both were higher in patients with synchronous metastases compared to metachronous ones and sPD-L1 was also higher for metastatic patients compared to non-metastatic patients. sPD-1 was also associated with the International Metastatic Renal Cell Cancer Database Consortium (IMDC) prognostic groups in metastatic CCRCC and also to the Morphology, Attenuation, Size and Structure (MASS) response criteria in metastatic patients treated with systemic therapy, mainly tyrosine-kinase inhibitors. Regarding prognosis, PD-L1 immunostaining at the tumor center with and without the tumor front was associated with worse su

Details

Database :
OAIster
Notes :
The work was funded by the Basque Government (ELKARTEK KK2018-00090 and KK-2020/00069)., English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1241091462
Document Type :
Electronic Resource